Possibly even more interestingly from a clinical perspective, the authors could utilize their system to propose a case-specific TRAIL-sensitizing strategy by analyzing the expression profiles from individual cell lines.137 Although these findings will require further validation in primary cancer cells and in vivo, this new and promising approach could prove to be valuable, given the recent advances in quantitative proteomics, which could enable the determination of protein expression profiles from patient-derived cancer tissue. The gene discussed is TNFSF10; the disease is cancer.